What is your preferred neoadjuvant chemotherapy regimen for muscle invasive bladder cancer, adequate performance status and preserved kidney function?

I agree, to date there is a lack of published randomized phase 3 data to date (though this is ongoing with NCT01812369) Several retrospective analyses such as one by Peyton et al JAMA Oncol 2019 found that neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) produced...

Preferred is clinical trial; except for that, I consider either accelerated (dose dense) MVAC every 2 weeks with G-CSF or gemcitabine/cisplatin (21-day cycle). Relevant data include S8710 phase 3 trial, EORTC-MRC phase 3 trial, meta-analysis, recent S1314 (COXEN trial), Plimack et al. JCO 2014, Chou...